drugset / Trial / NCT00562120

A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge

NCT00562120

Phase 2 Completed 21 enrolled Pfizer
RandomizedCrossoverDouble-blindTreatment

Summary

An H3 receptor antagonist should reduce the congestion associated with allergic rhinitis. A nasal allergen challenge will be given to patients to induce rhinitis symptoms and acoustic rhinometry will be used to measure the congestion.

Timeline

Start
2007-12
Primary completion
2008-08
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Allegra-D Unknown Oral
Comparator Fexofenadine Unknown Oral
Subject PF-03654746 Small molecule Oral

Indications